Key result
Cardiac resynchronization therapy failed to restore the significantly decreased levels of regulatory T cells in patients with chronic heart failure at 6 months follow-up.
Why the study?
Cardiac resynchronization therapy improves symptoms and cardiac remodeling in chronic heart failure, but its impact on the inflammatory immune response remains controversial.
Does cardiac resynchronization therapy restore T regulatory cell homeostasis in patients with chronic heart failure?
Cohort (n=50)
No
Does cardiac resynchronization therapy restore T regulatory cell homeostasis in patients with chronic heart failure?
Absolute Event Rate: 0.61% vs 1.08%
p-value: p=0.003
Cardiac resynchronization therapy does not restore the diminished levels of regulatory T cells or inhibit pro-inflammatory T cell pathways in patients with chronic heart failure.
No takes yet. Share an insight, caveat, or question.
CRT does not restore diminished Tregs in heart failure; leaves open immunomodulatory adjuncts.
António et al. (2022) conducted a cohort in Chronic heart failure (n=50). Cardiac resynchronization therapy (CRT) vs. Healthy controls and baseline (pre-CRT) was evaluated on T regulatory (Treg) cells frequency (p=0.003). Cardiac resynchronization therapy failed to restore the significantly decreased levels of regulatory T cells in patients with chronic heart failure at 6 months follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: